- Home
- LEGH vs DNTH Comparison
LEGH vs DNTH Comparison
Compare LEGH & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEGH
- DNTH
- Stock Information
- Founded
- LEGH 2005
- DNTH 2015
- Country
- LEGH United States
- DNTH United States
- Employees
- LEGH N/A
- DNTH N/A
- Industry
- LEGH Homebuilding
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- LEGH Consumer Discretionary
- DNTH Health Care
- Exchange
- LEGH Nasdaq
- DNTH Nasdaq
- Market Cap
- LEGH 588.8M
- DNTH 606.2M
- IPO Year
- LEGH 2018
- DNTH N/A
- Fundamental
- Price
- LEGH $22.75
- DNTH $21.50
- Analyst Decision
- LEGH Strong Buy
- DNTH Strong Buy
- Analyst Count
- LEGH 2
- DNTH 8
- Target Price
- LEGH $29.00
- DNTH $53.00
- AVG Volume (30 Days)
- LEGH 79.7K
- DNTH 387.8K
- Earning Date
- LEGH 08-07-2025
- DNTH 08-07-2025
- Dividend Yield
- LEGH N/A
- DNTH N/A
- EPS Growth
- LEGH 8.04
- DNTH N/A
- EPS
- LEGH 2.29
- DNTH N/A
- Revenue
- LEGH $176,618,000.00
- DNTH $6,524,000.00
- Revenue This Year
- LEGH N/A
- DNTH N/A
- Revenue Next Year
- LEGH $7.69
- DNTH N/A
- P/E Ratio
- LEGH $9.89
- DNTH N/A
- Revenue Growth
- LEGH N/A
- DNTH 102.36
- 52 Week Low
- LEGH $21.58
- DNTH $13.37
- 52 Week High
- LEGH $29.31
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- LEGH 49.32
- DNTH 61.73
- Support Level
- LEGH $22.32
- DNTH $19.90
- Resistance Level
- LEGH $23.32
- DNTH $22.49
- Average True Range (ATR)
- LEGH 0.60
- DNTH 1.43
- MACD
- LEGH -0.05
- DNTH 0.22
- Stochastic Oscillator
- LEGH 39.33
- DNTH 64.11
About LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.